Show simple item record

dc.contributor.authorEmerling, B. M.
dc.contributor.authorRicoult, S. J. H.
dc.contributor.authorBell, Eric L.
dc.contributor.authorGuarente, Leonard Pershing
dc.date.accessioned2013-11-18T18:12:13Z
dc.date.available2013-11-18T18:12:13Z
dc.date.issued2011-02
dc.date.submitted2011-01
dc.identifier.issn0950-9232
dc.identifier.issn1476-5594
dc.identifier.urihttp://hdl.handle.net/1721.1/82192
dc.description.abstractIt has become increasing clear that alterations in cellular metabolism have a key role in the generation and maintenance of cancer. Some of the metabolic changes can be attributed to the activation of oncogenes or loss of tumor suppressors. Here, we show that the mitochondrial sirtuin, SirT3, acts as a tumor suppressor via its ability to suppress reactive oxygen species (ROS) and regulate hypoxia inducible factor 1α (HIF-1α). Primary mouse embryo fibroblasts (MEFs) or tumor cell lines expressing SirT3 short-hairpin RNA exhibit a greater potential to proliferate, and augmented HIF-1α protein stabilization and transcriptional activity in hypoxic conditions. SirT3 knockdown increases tumorigenesis in xenograft models, and this is abolished by giving mice the anti-oxidant N-acetyl cysteine. Moreover, overexpression of SirT3 inhibits stabilization of HIF-1α protein in hypoxia and attenuates increases in HIF-1α transcriptional activity. Critically, overexpression of SirT3 decreases tumorigenesis in xenografts, even when induction of the sirtuin occurs after tumor initiation. These data suggest that SirT3 acts to suppress the growth of tumors, at least in part through its ability to suppress ROS and HIF-1α.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.). Ruth L. Kirschstein National Research Service Award (Postdoctoral Fellowship)en_US
dc.description.sponsorshipAmerican Cancer Society (Postdoctoral Fellowship)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.)en_US
dc.description.sponsorshipPaul F. Glenn Foundationen_US
dc.language.isoen_US
dc.publisherNature Publishing Groupen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/onc.2011.37en_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/en_US
dc.sourcePMCen_US
dc.titleSirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS productionen_US
dc.typeArticleen_US
dc.identifier.citationBell, E L, B M Emerling, S J H Ricoult, and L Guarente. “SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production.” Oncogene 30, no. 26 (February 28, 2011): 2986-2996. © 2011 Nature Publishing Groupen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.departmentPaul F. Glenn Center for Biology of Aging Research (Massachusetts Institute of Technology)en_US
dc.contributor.mitauthorBell, Eric L.en_US
dc.contributor.mitauthorGuarente, Leonard Pershingen_US
dc.relation.journalOncogeneen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsBell, E L; Emerling, B M; Ricoult, S J H; Guarente, Len_US
dc.identifier.orcidhttps://orcid.org/0000-0003-4064-2510
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record